SCHEMBL7192146

SCHEMBL7192146

CCOC(=O)CC(NC(=O)C(C)c1ccccc1)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
LMNA P02545 3/20 0.61
KDM4E B2RXH2 2/20 0.61
MAPT P10636 1/20 0.56
L3MBTL1 Q9Y468 3/20 0.55
HPGD P15428 1/20 0.55
CYP26A1 O43174 1/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ITGB3 P05106 1/20 0.43
ITGAV P06756 1/20 0.43
ITGA2B P08514 1/20 0.43
ITGB5 P18084 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7190164 0.89 ALDH1A1 (0.60) ALDH1A1LMNAKDM4EMAPTL3MBTL1
SCHEMBL7193876 0.87 ALDH1A1 (0.55) ALDH1A1LMNAKDM4EMAPTL3MBTL1
SCHEMBL7197522 0.86 ALDH1A1 (0.54) ALDH1A1LMNAKDM4EMAPTL3MBTL1
SCHEMBL7197279 0.86 ALDH1A1 (0.67) ALDH1A1LMNAKDM4EMAPTL3MBTL1
SCHEMBL13331128 0.84 ALDH1A1 (0.59) ALDH1A1LMNAKDM4EMAPTL3MBTL1
SCHEMBL13619485 0.84 ALDH1A1 (0.59) ALDH1A1LMNAKDM4EMAPTL3MBTL1
SCHEMBL8240159 0.84 ALDH1A1 (0.59) ALDH1A1LMNAKDM4EMAPTL3MBTL1
SCHEMBL14186062 0.83 ALDH1A1 (0.63) ALDH1A1LMNAKDM4EMAPTL3MBTL1
SCHEMBL7194448 0.83 GPR88 (0.45) ALDH1A1LMNAKDM4E
SCHEMBL7194108 0.82 L3MBTL1 (0.60) ALDH1A1LMNAKDM4EMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6589972-B2 Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects BAYER AKTIENGESELLSCHAFT (DE) 2003-07-08 US disclosed
EP-1147079-A2 BETA-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS Bayer Aktiengesellschaft (DE) 2001-10-24 EP disclosed
US-20010031788-A1 Beta-phenylalanine derivatives as integrin antagonists SCHOOP ANDREAS (DE) 2001-10-18 US disclosed
US-6291503-B1 β-phenylalanine derivatives as integrin antagonists BAYER AKTIENGESELLSCHAFT (DE) 2001-09-18 US disclosed
WO-2000041469-A2 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031788-A1 Beta-phenylalanine derivatives as integrin antagonists ITGB4, ITGA4, ITGB2 ALDH1A1 2010/4885LMNA 2949/4885KDM4E 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.